MRI Assessment of Leukemia Response to Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01537159|
Recruitment Status : Recruiting
First Posted : February 23, 2012
Last Update Posted : August 4, 2017
|Condition or disease||Intervention/treatment|
|Acute Myelogenous Leukemia||Device: 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Quantitative DCE-MRI as a Predictor of Therapeutic Response in Acute Leukemia|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||December 31, 2018|
Acute Myelogenous Leukemia (AML)
Patients who have been diagnosed with AML
Device: 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
Other Name: Magnetic Resonance Imaging (MRI)
- Shutter-Speed Model [ Time Frame: Up to 1 year ]To explore if Shutter-Speed Model (SSM) dynamic contrast-enhanced MRI (DCE-MRI)of the bone marrow (BM) can predict complete remission (CR) in newly diagnosed or relapsed acute myelogenous leukemia (AML)patients.
- Pilot Data [ Time Frame: Up to 1 year ]To collect pilot data in SSM DCE-MRI assessment of AML response to therapy for the conduct of future studies.
- Complete Response [ Time Frame: Up to 1 year ]To explore whether SSM DCE-MRI differs in predicting complete response (CR) for the newly diagnosed AML patients and for the relapsed AML patients.
- Second SSM DCE-MRI [ Time Frame: Up to 1 year ]To explore if the second SSM DCE-MRI and/or changes between the first and second imaging studies can predict CR in the non-CR group who undergo an additional therapy.
- DCE-MRI Biomarkers [ Time Frame: Up to 1 year ]To compare/correlate/combine DCE-MRI bio-markers with micro-vascular density (MVD) and proangiogenic cytokine profiles for the purpose of predicting response of AML patients to therapy.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01537159
|Contact: Alina Tudoricaemail@example.com|
|United States, Oregon|
|Oregon Health and Science University||Recruiting|
|Portland, Oregon, United States, 97239|
|Contact: Alina Tudorica firstname.lastname@example.org|
|Principal Investigator: Wei Huang, PhD|
|Principal Investigator:||Wei Huang, PhD||OHSU Knight Cancer Institute|